Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553803 | 0.85 | KDM4E (0.44) | ALDH1A1GAAKMT2ATDP1MAPT | |
| SCHEMBL2212689 | 0.84 | MAPT (0.49) | ALDH1A1GAAKMT2ATDP1MAPT | |
| SCHEMBL7764924 | 0.84 | MMP2 (0.49) | ALDH1A1ALOX15GAAKMT2ATDP1 | |
| SCHEMBL11036461 | 0.84 | AKT1 (0.42) | ALDH1A1ALOX15GAAKMT2ATDP1 | |
| SCHEMBL4041905 | 0.79 | ALDH1A1 (0.48) | ALDH1A1ALOX15GAAKMT2ATDP1 | |
| SCHEMBL6372852 | 0.78 | ALDH1A1 (0.56) | ALDH1A1ALOX15GAAKMT2ATDP1 | |
| SCHEMBL3260995 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALOX15GAAKMT2ATDP1 | |
| SCHEMBL27961101 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALOX15GAAKMT2ATDP1 | |
| SCHEMBL5830287 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALOX15GAAKMT2ATDP1 | |
| SCHEMBL5436325 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALOX15GAAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | claimed |
| EP-3238708-A1 | INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-1732512-B1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| EP-2440261-B1 | A CATHETER LOCKING SOLUTION HAVING ANTIMICROBIAL AND ANTICOAGULATION PROPERTIES | BECTON DICKINSON CO (US) | 2016-08-24 | — | — | EP | claimed |
| US-7816374-B2 | Administering to respiratory system an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof; chronic obstructive pulmonary disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2010-10-19 | — | — | US | claimed |
| EP-2043599-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20090054485-A1 | Method of treating neutrophil-related diseases with topical anesthetics | GLEICH GERALD J | 2009-02-26 | — | — | US | claimed |
| EP-1732512-A4 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1718276-A4 | INHALANT FORMULATION CONTAINING SULFOALKYLETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | CYDEX INC (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1729724-A4 | INHALENT FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRYN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2001028550-A1 | TOPICAL ANESTHETICS USEFUL FOR TREATING CANCER, AUTOIMMUNE DISEASES AND ISCHEMIA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2000003743-A9 | USE OF INHIBITORS OF PRENYLTRANSFERASES FOR INHIBITING FUNGAL GROWTH | MITOTIX INC (US) | 2000-07-27 | — | — | WO | claimed |
| EP-0979085-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2000-02-16 | — | — | EP | claimed |
| WO-2000003743-A2 | USE OF INHIBITORS OF PRENYLTRANSFERASES FOR INHIBITING FUNGAL GROWTH | MITOTIX, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| US-5837713-A | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-11-17 | — | — | US | claimed |
| WO-1998037896-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-09-03 | — | — | WO | claimed |
| US-5631267-A | BRONCHIAL ASTHMA, NASAL AND SINUS INFLAMMATION, RHINITIS, CONJUNCTIVITIS | MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH (US) | 1997-05-20 | — | — | US | claimed |
| US-5602098-A | ANTICANCER AGENT | UNIVERSITY OF PITTSBURGH (US) | 1997-02-11 | — | — | US | claimed |
| US-5510339-A | REDUCING STEROID THERAPY DEPENDENCE BY COUNTERACT THE SYMPTOMS OF ASTHMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1996-04-23 | — | — | US | claimed |
| WO-1994017790-A9 | USE OF TOPICAL ANESTHETICS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BRONCHIAL ASTHMA | — | 1994-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | ALDH1A1 3233/4885ALOX15 2775/4885GAA 786/4885 |
| US-20090054485-A1 | Method of treating neutrophil-related diseases with topical anesthetics | MMP8, ELANE, MPO | ALDH1A1 1299/4885ALOX15 81/4885GAA 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.